Novavax at underperform by RBC

RBC Capital Markets analyst Ken Trbovich rated Novavax Inc. at underperform, speculative risk. Data from GlaxoSmithKline study is a setback for Novavax and other early stage companies looking to turn fears of a pandemic into a robust vaccine business. GlaxoSmithKline used its proprietary adjuvant to immunize more than 80% of patients against H5N1 using a very low dose of antigen. Seasonal flu supply is expected to reach 120 million to 130 million in the United States, which is not good news for Novavax and its efforts to target the seasonal flu market, according to the analyst. Shares of the Malvern, Pa.-based biopharmaceutical company were unchanged at $3.70 on volume of 1,022,931 shares versus the three-month running average of 2,767,140 shares. (Nasdaq: NVAX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.